Leap Therapeutics (LPTX) shares were down nearly 13% in recent trading Wednesday after Baird and HC Wainwright downgraded the stock to neutral.
Baird also trimmed its price target to $1.25 from $9. The stock was previously rated outperform at Baird and buy at HC Wainwright.
Almost 3 million shares traded so far, compared with a daily average of about 612,000.
Price: 0.57, Change: -0.08, Percent Change: -12.92